cryopreservation

PreclinicalBiologic

CCentral Hospital, Nancy, France

cryopreservation is one of 42 biologic programs targeting Graft Versus Host Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Graft Versus Host DiseaseActive, not recruiting

Graft Versus Host DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Graft Versus Host Disease

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

15 2

Neoral

Novartis

Approved

9 3

Medrol

Pfizer

Approved

4 4

Selzentry

GSK

Approved

1 5

Gleevec

Olumiant

Defitelio

Nipent

Qvar

3 10

Cellcept

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Graft Versus Host Disease1 trial

Cryopreservation of White Blood Cells Before Their UVA Irradiation for Graft Versus Host Disease Treatment

Unknown status·—·N/A·NCT03361254·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cryopreservation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cryopreservation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cryopreservation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Central Hospital, Nancy, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentral Hospital, Nancy, France

cryopreservation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News